Pivot Park: a unique ecosystem
Pivot Park is the hotspot for pharmaceutical innovation in Brabant. It is also one of BOM's key partners in supporting start-ups developing new drugs and vaccines. In this video Brigitte Drees (Pivot Park), Helmuth van Es (Citryll) and Alexander Willemse (BioConnection B.V.) talk about a unique ecosystem at Pivot Park in Oss, where 60 companies are now located.
Read moreImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
IMMUNOPRECISE ANTIBODIES LTD., a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company’s subsidiary, IPA Europe, has been granted a three-year approval for the “Crédit d’Impôt Recherche” (CIR) from the French Ministry of Higher Education and Research.
Read moreArdena has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs.
Ardena has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs. The acquisition from SUANFARMA delivers expansion across Southern Europe and supports Ardena’s strategy to become a leading global CDMO, offering integrated solutions across the full pharma development lifecycle.
Read moreEerste studenten lectoraat Drug Discovery in september op Pivot Park
Het lectoraat Drug Discovery van de Academie Toegepaste Biowetenschappen en Chemie in Nijmegen start in september met zijn eerste studenten op het lab op Pivot Park. Het lectoraat maakt deel uit van de HAN University of Applied Sciences. We zitten in de kelder van het RE-gebouw (0201), een lab waar we zowel biologische als chemische onderwerpen kunnen adresseren en waar ongeveer 10 tot 15 studenten tegelijk kunnen werken.
Read moreCitryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology
Citryll announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance.
Read moreSynergy between biopharma and academia
Pivot Park firmly believes in the importance of collaboration between biotech and academia, and therefore strongly supports its partners with its broad “knowledge network”, which includes the Institute for Complex Molecular Systems (ICMS) at the Eindhoven University of Technology (TU/e).
Read morePharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa
Pharming announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals for the distribution of RUCONEST® (Conestat alfa) in the Middle East and North Africa.
Read moreGlycostem obtained the Tissue Bank License, to support the production of our lead investigational product oNKord®.
Currently oNKord® is produced with cord blood from UK. The Tissue Bank License makes it possible to continue production after the Brexit transition period, to use raw materials from other countries outside the EU, for example US, in the future. They are continuing treating AML patients in the oNKord phase I/phase II clinical trial.
Read moreWelkom Van Iersel Luchtman Advocaten
Vanaf mei 2021 is ons advocatenkantoor aangesloten bij het Pivot Park. Als satellite tenant hebben we geen vast kantoor, maar zijn we altijd bereikbaar en beschikbaar om je (virtueel) te ontmoeten als daar behoefte aan is.
Read more